Table 1. Changes in outcome variables when evaluating effects of intravitreal bevacizumab from baseline to last visit (n=42).
| Baseline | At 1 month after the first IVB | P-valuea | Last visitb | P-valuea | |
|---|---|---|---|---|---|
| BCVA (LogMAR) | 0.35±0.34 | 0.38±0.37 | 0.699 | 0.32±0.36 | 0.359 |
| SRF GLD (μm) | 3203.738±1058.801 | 1987.452±1715.729 | <0.001 | 860.929±1233.122 | <0.001 |
| SRF height (μm) | 213.429±101.014 | 88.071±85.585 | <0.001 | 43.524±79.750 | <0.001 |
| Central macular thickness (μm) | 428.952±107.105 | 298.122±84.105 | <0.001 | 268.786±83.562 | <0.001 |
| SRF volume (mm3) | 0.987±0.776 | 0.483±0.752 | <0.001 | 0.185±0.480 | <0.001 |
| Subfoveal choroidal thickness (μm) | 419.588±135.203 | 422.057±135.625 | 0.074 | 400.211±120.691 | 0.008 |
Abbreviations: BCVA, best corrected visual acuity; GLD, greatest linear diameter; IVB, intravitreal bevacizumab; SRF, subretinal fluid; LogMAR, logarithm of minimal angle of resolution.
a
Compared with baseline using Wilcoxon's matched-pairs signed-rank test.
b
Mean number of injections was 1.9±0.8 during the mean follow-up of 8.6±7.7 months.